Clinical Trial Details

CheckMate 9KD USOR 17149

A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Prostate Cancer
Study Type: Interventional
Phase: II
Study Start Date: 01/08/2018
Study Completion Date: 11/2020

The purpose of this study is to assess the safety and efficacy of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in participants with castration-resistant prostate cancer that has spread.

 

NCT Number

NCT03338790

Principal Investigator(s)

Manish Agarwal, MD

Sponsor(s)

Bristol-Myers Squibb

Participant Eligibility

• Age: 18 - No Maximum
• Gender: Male, Female